NRx Pharmaceuticals, Inc.
NRXP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $242 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $97 | $0 | $0 | $1 |
| Gross Profit | $145 | $0 | $0 | -$1 |
| % Margin | 59.9% | – | – | – |
| R&D Expenses | $1,429 | $987 | $804 | $1,036 |
| G&A Expenses | $0 | $2,743 | $2,943 | $0 |
| SG&A Expenses | $2,808 | $2,743 | $2,943 | $2,597 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$68 | $0 | $100 | $0 |
| Operating Expenses | $4,169 | $3,730 | $3,847 | $3,633 |
| Operating Income | -$4,024 | -$3,730 | -$3,847 | -$3,634 |
| % Margin | -1,662.8% | – | – | – |
| Other Income/Exp. Net | -$1,866 | -$13,851 | -$1,665 | -$5,444 |
| Pre-Tax Income | -$5,890 | -$17,581 | -$5,512 | -$9,078 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5,890 | -$17,581 | -$5,512 | -$9,078 |
| % Margin | -2,433.9% | – | – | – |
| EPS | -0.27 | -0.98 | -0.34 | -0.86 |
| % Growth | 72.4% | -188.2% | 60.5% | – |
| EPS Diluted | -0.27 | -0.98 | -0.34 | -0.86 |
| Weighted Avg Shares Out | 22,231 | 17,934 | 16,410 | 10,517 |
| Weighted Avg Shares Out Dil | 22,231 | 17,934 | 16,410 | 10,517 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $4 | $4 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $43 | $0 | $0 | $1 |
| EBITDA | -$5,847 | -$17,581 | -$5,512 | -$9,077 |
| % Margin | -2,416.1% | – | – | – |